Back to top
more

Biohaven Ltd. (BHVN)

(Delayed Data from NYSE)

$38.97 USD

38.97
948,302

+0.43 (1.12%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $38.98 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is a Surprise Coming for Biohaven Pharmaceutical (BHVN) This Earnings Season?

Biohaven Pharmaceutical (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

OYSTER PT PHARM (OYST) Reports Q1 Loss, Tops Revenue Estimates

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -2.86% and 31.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates

Seer, Inc. (SEER) delivered earnings and revenue surprises of 7.32% and 18.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biohaven's (BHVN) Q4 Earnings Miss, Nurtec Gets CHMP Nod

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The CHMP recommends approval of Nurtec ODT. Stock declines.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -45.41% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of 23.53% and 4.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Report Negative Earnings Next Week? What You Should Know

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biohaven (BHVN) Migraine Drug Meets Study Goals in China

Biohaven (BHVN) and partner Pfizer announce positive top-line results from a phase III study on rimegepant for the acute treatment of migraine. The study meets the co-primary endpoints.

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 37.50% and 8.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Sweta Jaiswal, FRM headshot

Diversify Your Portfolio With a New Psychedelic Drug ETF

A new thematic ETF providing exposure to the medicinal psychedelic drug industry, PSYK ETF, has just been launched.

Ekta Bagri headshot

Biotech Stock Roundup: ACAD Up on Study Results, BHVN's Pipeline Update & More

Acadia's (ACAD) study results and other pipeline updates have been the biotech sector's few key highlights during the past week.

Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study

Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer

Biotech Stock Roundup: REGN, MRNA Post Q3 Earnings, SAVA Gains on AD Review Data

Earnings and other updates from bigwigs like Regeneron (REGN) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.

Biohaven (BHVN) Misses on Q3 Earnings, Inks $1.24B Pfizer Deal

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The company signs an agreement with Pfizer, granting the latter ex-U.S. marketing rights to Nurtec ODT.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q3 Loss, Tops Revenue Estimates

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -7.79% and 1.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Report Negative Q3 Earnings? What You Should Know

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biohaven (BHVN) Q3 Nurtec Preliminary Sales Top Expectations

Biohaven's (BHVN) sole marketable drug, Nurtec ODT reports preliminary sales for the third quarter, which beat expectations.

Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More

Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week.

AbbVie's (ABBV) Migraine Prevention Drug Qulipta Gets FDA Nod

The FDA approves AbbVie's (ABBV) Qulipta (atogepant) for preventive treatment of episodic migraine in adults.

Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails

Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-stage study.

Why Is Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 21.7% Since Last Earnings Report?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong

Biohaven's (BHVN) sole approved drug, Nurtec ODT for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -16.61% and 0.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?